Michael Traxlmayr

Priv.-Doz. Dipl.-Ing. Dr. Michael Traxlmayr
Institut für Biochemie (DCH/BC)
Standort Gregor-Mendel-Straße 33, 1180 Wien
Email michael.traxlmayr@boku.ac.at
Tel: +43 1 47654-77274

ORCID: 0000-0002-2108-582X
55008094000: AuthorId

Meine Lehrveranstaltungen

Biochemie

Laufbahn

2022 Habilitation
2017 Senior Scientist (BOKU)
2016 - 2017 Postdoc (BOKU)
2013 - 2015 Postdoc (Massachusetts Institute of Technology, MIT)
2008 - 2012 Dissertation (BOKU)
2002 - 2008 Diplomstudium Lebensmittel- und Biotechnologie (BOKU)

Auszeichnungen

2020 BOKU invention of the year
2013 BOKU Talent Award
2013 Schrödinger fellowship for postdoctoral research at MIT
2013 ÖGMBT doctoral thesis award (Austrian Association of Molecular Life Sciences and Biotechnology)

Projekte

Es wurden 0 Projekte gefunden.

Publikationen

Wissentransfer in die Gesellschaft

Medienbeiträge

Vorträge

(2024) Engineering of molecular ON- and OFF-switches for controlling CAR T cells

Autoren: Charlotte U. Zajc, Delia Sumesgutner, Julia Mayer, Elise Sylvander, Magdalena Teufl, Manfred Lehner, Michael W. Traxlmayr

EBMT-EHA 6th European CAR T-cell Meeting
(2023) Engineering molecular switches for functional control of CAR T cells with an orally available small molecule drug.

Autoren: Zajc, CU; Dobersberger, M; Schaffner, I; Mlynek, G; Pühringer, D; Salzer, B; Djinović-Carugo, K; Obinger, C; Lehner, M; Traxlmayr, MW

EHA-EBMT 5th European CAR T-cell Meeting
(2023) Novel protein engineering strategies for next-generation CAR T-cells.

Autoren: Traxlmayr, MW

Janssen R&D Symposium on Next-Generation Cell Therapy
(2023) Unraveling the FMC63-CD19 affinity

Autoren: Seigner, J; Zajc, CU; Dötsch, S; Eigner, C; Laurent, E; Busch, DH; Lehner, M; Traxlmayr, MW

Keystone meeting on Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy
(2023) Incorporating drug regulated switch modules to improve the safety of cellular therapies.

Autoren: Traxlmayr, MW

Gamma Delta T Therapies Summit, Boston
(2023) Novel protein engineering concepts to improve the safety and specificity of CAR T cells

Autoren: Traxlmayr, MW

PEGS Boston
(2023) Taking control of CAR T cells- Engineering of molecular ON-switches for cellular therapies

Autoren: Charlotte U. Zajc, Markus Dobersberger, Manfred Lehner and Michael W. Traxlmayr

ÖGMBT Annual Meeting
(2023) Novel Concepts to Regulate CAR T Cell Activity with Small Molecule Drugs in Vivo

Autoren: Traxlmayr, MW

PEGS Europe
(2022) Entwicklung von stabilisierten CD19-Varianten für die Detektion und Affinitätsanalyse von CAR-T Zellen

Autoren: Michael W. Traxlmayr

CAR-T Cell Network Meeting
(2022) PhosphoFlowSeq – a novel high-throughput kinase activity assay for the identification of drug resistance mutations in EGFR

Autoren: Teufl, M; Wagner, A; Gold, L; Lehner, M; Obinger, C; Sykacek, P; Traxlmayr, M

PEGS Europe 2022
(2022) Reversible control of CAR-T therapy to reduce toxicity and improve clinical outcomes

Autoren: Michael W. Traxlmayr

Onco Cell Therapy Summit Europe
(2020) Detailed analysis of lipocalin-based molecular ON-switches in biochemical assays and in CAR T cells

Autoren: Brey, CU; Dobersberger, M; Schaffner, I; Salzer, B; Steinberger, P; De Sousa Linhares, A; Lehner, M; Traxlmayr, MW

Keystone Symposia meeting on Emerging Cellular Therapies: Cancer and Beyond
(2020) A conformation-specific ON-switch for controlling CAR T cells with an orally available drug

Autoren: Brey, C.U.; Dobersberger, M.; Schaffner, I.; Salzer, B.; Obinger, C.; Holter, W.; Traxlmayr, M.W.; Lehner, M.

Keystone-Emerging cellular therapies
(2019) AVIDCARS - A NOVEL PLATFORM FOR INTEGRATION OF MULTIPLE INPUT SIGNALS BY ONE CAR MOLECULE

Autoren: Salzer, B; Brey, CU; Schueller, C; Schoeber, M; Lobner, E; Dushek, O; Holter, W; Traxlmayr, MW; Lehner, M

International Conference on Lymphocyte Engineering (ICLE)
(2019) A LIPOCALIN-BASED ON-SWITCH FOR CONTROLLING CAR T CELLS WITH AN ORALLY AVAILABLE DRUG

Autoren: Brey, C; Dobersberger, M; Schaffner, I; Mlynek, G; P?hringer, D; Salzer, B; Djinovic-Carugo, K; Obinger, C; Holter, W; Traxlmayr, M; Lehner, M

International Conference on Lymphocyte Engineering (ICLE)
(2019) Moderne Krebsforschung – Neue Chancen durch personalisierte Medizin?

Autoren: Heffeter, P; Jäger, U; Traxlmayr, M

Science Talk
(2017) Development of a FACS-based screening for H2O2 producing oxidoreductases using GFP derived sensors

Autoren: Herzog, PL; Brugger, D; Sützl, L; Traxlmayr, M; Obinger, C; Haltrich, D; Peterbauer CK

19th International Symposium on Flavins and Flavoproteins 2017
(2016) Structures and thermodynamics of Fcab-antigen complexes.

Autoren: Lobner, E., Humm, A.-S., Göritzer, K., Mlynek, G., Hasenhindl, C., Traxlmayr, M., Djinoviv-Carugo, K., Obinger, C.

PEGS 2016
(2016) A hyperstable miniprotein as an alternative to antibodies

Autoren: Traxlmayr, MW; Kiefer, JD; Srinivas, RR; Lobner, E; Tisdale, AW; Mehta, NK; Tidor, B; Wittrup KD

8th ÖGMBT Annual Meeting 2016
(2014) A Hyperstable Minimalist Protein for Molecular Recognition

Autoren: Traxlmayr, MW; Srinivas, RR; Lobner, E; Tidor, B; Wittrup, KD

28th Annual Symposium of the Protein-Society 2014
(2014) Construction of pH-sensitive Her2 binding antibody fragment by directed evolution using yeast display

Autoren: Lobner, E., Traxlmayr, M. W., Rueker, F., Obinger, C.

The 16th European Congress on Biotechnology
(2012) Systematic analysis of the C-terminal loops of IgG1-Fc for their usability in Modular Antibody Engineering

Autoren: Hasenhindl, C., Wozniak-Knopp1, G., Traxlmayr, M.W., Hackl, M., Stadlmayr, G., Rüker F. and Obinger C.

9th International Conference on Protein Stability 2012 - From molecular level to market applications
(2012) Measures to Enhance Half-Life and Stability (Preconference Short Course)

Autoren: Rüker, F; Traxlmayr, M;

Protein and Antibody Engineering Summit PEGS Europe 2012
(2012) Stability engineering of human IgG1-Fc to resist boiling

Autoren: Stadlmayr, G., Schaffner, I., Traxlmayr, M., Wozniak-Knopp, G., Hasenhindl, C., Rüker, F. and Obinger, C.

9th International Conference on Protein Stability 2012 - From molecular level to market applications
(2012) Stability engineering of IgG1-Fc and construction of a “protein stability landscape” by high throughput sequencing

Autoren: Traxlmayr, M.W.Faissner, M., Hasenhindl, C., Hackl, M., Stadlmayr, G., Rüker, F. and Obinger, C.

9th International Conference on Protein Stability 2012 - From molecular level to market applications
(2011) Stability engineering of human IgG1-Fc and application in modular antibody engineering

Autoren: Hasenhindl,C., Traxlmayr, M. W., Faissner, M., Stadlmayr, G., Rüker, F., Obinger, C.

3rd PEGS Europe Protein & Antibody Engineering Summit 2011
(2011) Stability-engineering of human IgG1-Fc by using yeast display

Autoren: Traxlmayr, M. W., Faissner, M., Stadlmayr, G., Rüker, F., Obinger, C.

PEGS - Protein and Antibody Engineering Summit 2011
(2009) Engineered human IgG1-Fc binding to integrin

Autoren: Traxlmayr, M., Wozniak-Knopp, G., Rüker, F., Obinger, C.

20th IBC's Annual International Conference on Antibody Engineering 2009
Directed evolution of antibody fragments for improved stability and resistance to aggregation by using yeast surface display

Autoren: Lobner, E., Traxlmayr, M. W., Rüker, F., Obinger, C.
Stability assessment on a library scale – A rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc.

Autoren: Hasenhindl, C., Traxlmayr, M.W., Wozniak-Knopp, G ., Jones, P.C., Stadlmayr, G., Rüker, F., Obinger, C.
Construction of a molecular ON-switch for controlling CAR T cells with an orally available small molecule

Autoren: Brey, CU; Dobersberger, M; Schaffner, I; Mlynek, G; Pühringer, D; Salzer, B; Djinović-Carugo. K; Obinger, C; Holter, W; Lehner, M; Traxlmayr, MW

Michael Traxlmayr

Laufbahn

Auszeichnungen

Projekte

Publikationen

Wissentransfer in die Gesellschaft

Medienbeiträge

Vorträge

(2024) Engineering of molecular ON- and OFF-switches for controlling CAR T cells

(2023) Engineering molecular switches for functional control of CAR T cells with an orally available small molecule drug.

(2023) Novel protein engineering strategies for next-generation CAR T-cells.

(2023) Unraveling the FMC63-CD19 affinity

(2023) Incorporating drug regulated switch modules to improve the safety of cellular therapies.

(2023) Novel protein engineering concepts to improve the safety and specificity of CAR T cells

(2023) Taking control of CAR T cells- Engineering of molecular ON-switches for cellular therapies

(2023) Novel Concepts to Regulate CAR T Cell Activity with Small Molecule Drugs in Vivo

(2022) Entwicklung von stabilisierten CD19-Varianten für die Detektion und Affinitätsanalyse von CAR-T Zellen

(2022) PhosphoFlowSeq – a novel high-throughput kinase activity assay for the identification of drug resistance mutations in EGFR

(2022) Reversible control of CAR-T therapy to reduce toxicity and improve clinical outcomes

(2020) Detailed analysis of lipocalin-based molecular ON-switches in biochemical assays and in CAR T cells

(2020) A conformation-specific ON-switch for controlling CAR T cells with an orally available drug

(2019) AVIDCARS - A NOVEL PLATFORM FOR INTEGRATION OF MULTIPLE INPUT SIGNALS BY ONE CAR MOLECULE

(2019) A LIPOCALIN-BASED ON-SWITCH FOR CONTROLLING CAR T CELLS WITH AN ORALLY AVAILABLE DRUG

(2019) Moderne Krebsforschung – Neue Chancen durch personalisierte Medizin?

(2017) Development of a FACS-based screening for H2O2 producing oxidoreductases using GFP derived sensors

(2016) Structures and thermodynamics of Fcab-antigen complexes.

(2016) A hyperstable miniprotein as an alternative to antibodies

(2014) A Hyperstable Minimalist Protein for Molecular Recognition

(2014) Construction of pH-sensitive Her2 binding antibody fragment by directed evolution using yeast display

(2012) Systematic analysis of the C-terminal loops of IgG1-Fc for their usability in Modular Antibody Engineering

(2012) Measures to Enhance Half-Life and Stability (Preconference Short Course)

(2012) Stability engineering of human IgG1-Fc to resist boiling

(2012) Stability engineering of IgG1-Fc and construction of a “protein stability landscape” by high throughput sequencing

(2011) Stability engineering of human IgG1-Fc and application in modular antibody engineering

(2011) Stability-engineering of human IgG1-Fc by using yeast display

(2009) Engineered human IgG1-Fc binding to integrin

Directed evolution of antibody fragments for improved stability and resistance to aggregation by using yeast surface display

Stability assessment on a library scale – A rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc.

Construction of a molecular ON-switch for controlling CAR T cells with an orally available small molecule

Betreute Hochschulschriften

Community Services